News

BMJ1d
Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use
Background The effects of fish oil (FO) in rheumatoid arthritis (RA) have not been examined in the context of contemporary treatment of early RA. This study examined the effects of high versus low ...
BMJ2d
Rituximab in the treatment of antisynthetase syndrome
Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland Correspondence to: Professor C Gabay Division of Rheumatology, Department of Internal ...
BMJ4d
A disease activity score for polymyalgia rheumatica
Objective: To develop a composite score for measurement of disease activity in polymyalgia rheumatica (PMR) and assess its internal and external validity. Methods: A PMR activity score (AS) was ...
BMJ5d
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis
Background An important but often insufficient aspect of care in people with inflammatory arthritis (IA) is empowering patients to acquire a good understanding of their disease and building their ...
BMJ5d
Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis
Objectives Clinical heterogeneity is a cardinal feature of systemic sclerosis (SSc). Hallmark SSc autoantibodies are central to diagnosis and associate with distinct patterns of skin-based and ...
BMJ5d
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout
Objective Gout is characterised by severe interleukin (IL)-1-mediated joint inflammation induced by monosodium urate crystals. Since IL-37 is a pivotal anti-inflammatory cytokine suppressing the ...
BMJ6d
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
4 Spire Sciences LLC, San Francisco, California, USA (and affiliated to Synarc Inc, San Francisco, California, USA during the majority of the manuscript development) 5 The Karolinska Institute, ...
BMJ6d
Increased mortality in ankylosing spondylitis is related to disease activity
1 Department of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway 2 Department of Rheumatology, Rikshospitalet-Radiumhospitalet University Hospital, Oslo, Norway Correspondence to ...
BMJ7d
Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial
1 Department of Rheumatology, Chinese PLA General Hospital, Beijing, People's Republic of China 2 Department of Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's ...
BMJ7d
Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis
Objective To identify predictors of poorer physical function in established psoriatic arthritis (PsA). Methods PsA patients with disease duration of ≥10 years were identified from the Bath ...
BMJ7d
Six months open label trial of leflunomide in active ankylosing spondylitis
Objective: To examine the potential therapeutic effects of leflunomide in patients with active AS in an open label study. Patients and methods: Twenty patients with AS fulfilling the 1984 modified New ...
BMJ7d
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
Objective: To examine the therapeutic effect of the interleukin 1 (IL1) receptor antagonist anakinra in ankylosing spondylitis in an open label trial. Methods: Anakinra (100 mg) was given ...